Client news and transactions
Recent client news
Entera prices $275 million PIPE, Israel’s largest biotech private placement
Oversubscribed private placement led by BVF Partners. Arx congratulates Miranda Toledano and the Entera team.
PolyPid partners with Azurity to commercialize D-PLEX100 in the U.S. and Canada
Up to $320 million-plus in payments and royalties. U.S. launch targeted for Q1 2027.
Nuvectis Pharma completes $100 million public offering
Nasdaq: NVCT prices 5,000,000 shares at $20.00. Proceeds to advance NXP100, NXP200 and NXP900.
Nuvectis expands pipeline with Haisco license for two clinical-stage compounds
Ex-China rights to HSK42360 and HSK39297. $40 million upfront and near-term, up to $1.42 billion in milestones.
QTREX raises $10 million as quantum interconnect story scales past $100 million market cap
$15M to $100M+ in just over eight weeks since the AME acquisition. Now a $10 million private placement from a fundamental institution.
Alpha Tau and Tolmar announce a U.S. prostate-cancer collaboration
Quantum Cyber raises more than $15 million and clears the cap table of debt
NASDAQ: QUCY. Full warrant exercise. All debt extinguished. An autonomous defense platform now funded for what comes next.
Duke Robotics closes $9.2 million offering and uplists to Nasdaq
NASDAQ: DUKR. From OTCQB micro-cap to Nasdaq in two years. Maxim Group sole bookrunner.
Evolution Metals secures $100 million from Yorkville Advisors
NASDAQ: EMAT. Multi-tranche convertible facility to expand U.S. critical-materials production.
Molex to acquire Teramount for a reported $430 million
Fiber-optic connectivity for AI chips and data centers. Signed during the war with Iran.
Inspira acquires Nano Dimension’s AME platform and launches QTREX
A highly specialized advanced manufacturing system — and a new quantum interconnect brand.
Entera closes $10 million BVF-led direct investment, with up to $24.5 million potential
NASDAQ: ENTX. A vote of confidence ahead of the EB613 Phase 3 registration study.
SalesCloser AI completes its qualifying transaction and lists on the TSX Venture
ARR from C$0.3M to over C$2.0M in just over a year. Expected to begin trading in the coming days.
Palatin prices an upsized $15.8 million offering and returns to NYSE American
NYSE: PTN. A.G.P. sole bookrunner. Trading expected to resume November 12, 2025.